PubMed

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes. An Asian perspective from the RENAAL Study.

Chan JC, Wat NM, So WY, Lam KS, Chua CT, Wong KS, Morad Z, Dickson TZ, Hille D, Zhang Z, Cooper ME, Shahinfar S, Brenner BM, Kurokawa K; Asian RENAAL Study Investigators.

Diabetes Care. 2004 Apr;27(4):874-9.PMID: 15047641 [PubMed - indexed for MEDLINE]Related articlesFree article

Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.

de Zeeuw D, Remuzzi G, Parving HH, Keane WF, Zhang Z, Shahinfar S, Snapinn S, Cooper ME, Mitch WE, Brenner BM.

Kidney Int. 2004 Jun;65(6):2309-20.PMID: 15149345 [PubMed - indexed for MEDLINE]Related articles

Effects of blood pressure level on progression of diabetic nephropathy: results from the RENAAL study.

Bakris GL, Weir MR, Shanifar S, Zhang Z, Douglas J, van Dijk DJ, Brenner BM; RENAAL Study Group.

Arch Intern Med. 2003 Jul 14;163(13):1555-65.PMID: 12860578 [PubMed - indexed for MEDLINE]Related articlesFree article

Renin angiotensin aldosterone system blockade and renal disease in patients with type 2 diabetes: a subanalysis of Japanese patients from the RENAAL study.

Kurokawa K, Chan JC, Cooper ME, Keane WF, Shahinfar S, Zhang Z.

Clin Exp Nephrol. 2006 Sep;10(3):193-200.PMID: 17009077 [PubMed - indexed for MEDLINE]Related articles

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.PMID: 11565518 [PubMed - indexed for MEDLINE]Related articlesFree article

Recent advances in management of type 2 diabetes and nephropathy: lessons from the RENAAL study.

Keane WF, Lyle PA; Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan study.

Am J Kidney Dis. 2003 Mar;41(3 Suppl 1):S22-5. Review.PMID: 12612946 [PubMed - indexed for MEDLINE]Related articles

Losartan in patients with type 2 diabetes and proteinuria: observations from the RENAAL Study.

Shahinfar S, Dickson TZ, Ahmed T, Zhang Z, Ramjit D, Smith RD, Brenner BM; RENAAL Investigators.

Kidney Int Suppl. 2002 Dec;(82):S64-7.PMID: 12410858 [PubMed - indexed for MEDLINE]Related articles

[Effect of losartan on renal and cardiovascular complications of patients with type 2 diabetes and nephropathy]

Parving HH, Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S.

Ugeskr Laeger. 2001 Oct 1;163(40):5514-9. Danish. PMID: 11601117 [PubMed - indexed for MEDLINE]Related articles

An economic evaluation of Losartan therapy in type 2 diabetic patients with nephropathy: an analysis of the RENAAL study adapted to France.

Souchet T, Durand Zaleski I, Hannedouche T, Rodier M, Gaugris S, Passa P; RENAAL study.

Diabetes Metab. 2003 Feb;29(1):29-35.PMID: 12629445 [PubMed - indexed for MEDLINE]Related articlesFree article

Use of losartan in diabetic patients in the primary care setting: review of the results in LIFE and RENAAL.

Egan B, Gleim G, Panish J.

Curr Med Res Opin. 2004 Dec;20(12):1909-17.PMID: 15701209 [PubMed - indexed for MEDLINE]Related articles

Losartan and end-organ protection--lessons from the RENAAL study.

Kowey PR, Dickson TZ, Zhang Z, Shahinfar S, Brenner BM; RENAAL Investigators.

Clin Cardiol. 2005 Mar;28(3):136-42.PMID: 15813620 [PubMed - indexed for MEDLINE]Related articles

Adverse effects of left ventricular hypertrophy in the reduction of endpoints in NIDDM with the angiotensin II antagonist losartan (RENAAL) study.

Boner G, Cooper ME, McCarroll K, Brenner BM, de Zeeuw D, Kowey PR, Shahinfar S, Dickson T, Crow RS, Parving HH; RENAAL Investigators.

Diabetologia. 2005 Oct;48(10):1980-7. Epub 2005 Aug 5.PMID: 16082528 [PubMed - indexed for MEDLINE]Related articles

Losartan reduces the costs of diabetic end-stage renal disease: an Asian perspective.

Seng WK, Hwang SJ, Han DC, Teong CC, Chan J, Burke TA, Carides GW, Choi YJ.

Nephrology (Carlton). 2005 Oct;10(5):520-4.PMID: 16221106 [PubMed - indexed for MEDLINE]Related articles

The role of angiotensin II antagonism in type 2 diabetes mellitus: a review of renoprotection studies.

Zanella MT, Ribeiro AB.

Clin Ther. 2002 Jul;24(7):1019-34. Review.PMID: 12182249 [PubMed - indexed for MEDLINE]Related articles

The losartan renal protection study--rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan).

Brenner BM, Cooper ME, de Zeeuw D, Grunfeld JP, Keane WF, Kurokawa K, McGill JB, Mitch WE, Parving HH, Remuzzi G, Ribeiro AB, Schluchter MD, Snavely D, Zhang Z, Simpson R, Ramjit D, Shahinfar S; RENAAL Study Investigators.

J Renin Angiotensin Aldosterone Syst. 2000 Dec;1(4):328-35.PMID: 11967819 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of angiotensin II receptor blockade in elderly patients with diabetes.

Winkelmayer WC, Zhang Z, Shahinfar S, Cooper ME, Avorn J, Brenner BM.

Diabetes Care. 2006 Oct;29(10):2210-7.PMID: 17003295 [PubMed - indexed for MEDLINE]Related articlesFree article

Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence.

Ruilope LM, Segura J.

Clin Ther. 2003 Dec;25(12):3044-64. Review.PMID: 14749145 [PubMed - indexed for MEDLINE]Related articles

Advances in the treatment of diabetic renal disease: focus on losartan.

Rayner B.

Curr Med Res Opin. 2004 Mar;20(3):333-40. Review.PMID: 15025842 [PubMed - indexed for MEDLINE]Related articles

The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, Ribeiro AB, Shahinfar S, Simpson RL, Snapinn SM, Toto R; RENAAL Study Investigators.

Kidney Int. 2003 Apr;63(4):1499-507.PMID: 12631367 [PubMed - indexed for MEDLINE]Related articles

Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union.

Gerth WC, Remuzzi G, Viberti G, Hannedouche T, Martinez-Castelao A, Shahinfar S, Carides GW, Brenner B.

Kidney Int Suppl. 2002 Dec;(82):S68-72.PMID: 12410859 [PubMed - indexed for MEDLINE]Related articles